FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on FGEN. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. HC Wainwright raised shares of FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th.

FibroGen Price Performance

Shares of NASDAQ:FGEN opened at $0.50 on Tuesday. The stock’s 50 day moving average price is $0.36 and its 200 day moving average price is $0.55. The stock has a market cap of $50.24 million, a price-to-earnings ratio of -0.41 and a beta of 0.82. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the previous year, the firm posted ($0.52) EPS. On average, sell-side analysts expect that FibroGen will post -0.86 EPS for the current year.

Hedge Funds Weigh In On FibroGen

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC grew its holdings in FibroGen by 34.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares during the last quarter. AQR Capital Management LLC grew its position in FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 769,586 shares during the last quarter. Geode Capital Management LLC raised its holdings in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of FibroGen during the third quarter valued at approximately $307,000. Finally, XTX Topco Ltd bought a new stake in FibroGen in the 2nd quarter valued at $424,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.